First-line chemoimmunotherapy combinations for newly diagnosed DLBCL
| Scheme (trial) . | Study phase . | No. of patients . | Median age (range) . | Biological characteristics . | ORR/CR (%) . | PFS/EFS (%) at time period . | OS (%) at time period . | Primary end point . | HR . |
|---|---|---|---|---|---|---|---|---|---|
| Venetoclax + R-CHOP (CAVALLI)1 | II | 206 | 65 (18-85) | All DLBCL | 83/69 | 80 (2 y) | 86 (2 y) | CR | — |
| Venetoclax + R-CHOP Bcl-2-positive patients (CAVALLI)1 | II | 104 | NA | All DLBCL | 83/64 | 78 (2 y) | 83 (2 y) | CR | — |
| Rituximab-CHOP2 | III | 202* | 69 (60-80) | All DLBCL | 82/52 | 57 (2 y) | 70 (2 y) | EFS | 0.58 |
| DA-EPOCH-R3 | III | 241* | 58 (19-84) | All DLBCL | 87/58 | 80 (2 y) | 86 (2 y) | PFS | 0.93 |
| HDC + ASCT4 | III | 199* | 48 (36-56) | All DLBCL | 79/76 | 70 (5 y) | 78 (5 y) | EFS | 0.65 |
| G-CHOP (GOYA)5 | III | 704* | 62 (18-86) | All DLBCL | 77/57 | 64 (5 y) | 77 (5 y) | PFS | 0.94 |
| Ibrutinib + R-CHOP (PHOENIX)7 | III | 419* | 63 (19-88) | Non-GCB | 89/67 | 70 (2 y)† | 85 (2 y)† | EFS | 0.93 |
| R2-CHOP (ROBUST)8 | III | 285* | 65 (21-82) | ABC | 91/69 | 75 (2 y)† | 79 (2 y) | PFS | 0.85 |
| RLI + R-CHOP‡ (SMART START)10 | Single-arm II | 60 | 63 (29-83) | Non-GCB | 100/95 | 92 (1 y) | 96 (1 y) | ORR/CR | — |
| Scheme (trial) . | Study phase . | No. of patients . | Median age (range) . | Biological characteristics . | ORR/CR (%) . | PFS/EFS (%) at time period . | OS (%) at time period . | Primary end point . | HR . |
|---|---|---|---|---|---|---|---|---|---|
| Venetoclax + R-CHOP (CAVALLI)1 | II | 206 | 65 (18-85) | All DLBCL | 83/69 | 80 (2 y) | 86 (2 y) | CR | — |
| Venetoclax + R-CHOP Bcl-2-positive patients (CAVALLI)1 | II | 104 | NA | All DLBCL | 83/64 | 78 (2 y) | 83 (2 y) | CR | — |
| Rituximab-CHOP2 | III | 202* | 69 (60-80) | All DLBCL | 82/52 | 57 (2 y) | 70 (2 y) | EFS | 0.58 |
| DA-EPOCH-R3 | III | 241* | 58 (19-84) | All DLBCL | 87/58 | 80 (2 y) | 86 (2 y) | PFS | 0.93 |
| HDC + ASCT4 | III | 199* | 48 (36-56) | All DLBCL | 79/76 | 70 (5 y) | 78 (5 y) | EFS | 0.65 |
| G-CHOP (GOYA)5 | III | 704* | 62 (18-86) | All DLBCL | 77/57 | 64 (5 y) | 77 (5 y) | PFS | 0.94 |
| Ibrutinib + R-CHOP (PHOENIX)7 | III | 419* | 63 (19-88) | Non-GCB | 89/67 | 70 (2 y)† | 85 (2 y)† | EFS | 0.93 |
| R2-CHOP (ROBUST)8 | III | 285* | 65 (21-82) | ABC | 91/69 | 75 (2 y)† | 79 (2 y) | PFS | 0.85 |
| RLI + R-CHOP‡ (SMART START)10 | Single-arm II | 60 | 63 (29-83) | Non-GCB | 100/95 | 92 (1 y) | 96 (1 y) | ORR/CR | — |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; EFS, event-free survival; G, obinutuzumab; HDC + ASCT, high-dose chemotherapy plus autologous stem cell transplantation; HR, hazard ratio; NA, not available; ORR, overall response rate; OS, overall survival; R, rituximab; R2, rituximab plus lenalidomide; RLI, rituximab, lenalidomide, and ibrutinib.
Considering experimental arm only.
Approximate data obtained from reported Kaplan-Meier curves.
CHOP or dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) per treating physician choice.